<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603719</url>
  </required_header>
  <id_info>
    <org_study_id>EWK-001</org_study_id>
    <nct_id>NCT01603719</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of an Infant Formula With Milkfat and Prebiotics</brief_title>
  <official_title>Safety and Efficacy of an Infant Starter Formula With Prebiotics (GOS) and a Higher Content of Beta-palmitate on Stool Characteristics, Food Tolerance, Calcium Uptake, and Incidence of Infectious Disease in the First Year of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Waldkrankenhaus Protestant Hospital, Spandau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Waldkrankenhaus Protestant Hospital, Spandau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the effect of a new infant starter formula
      with added prebiotics (GOS) and with a fat blend rich in beta-palmitate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An experimental infant formula with added prebiotics (GOS) and with a higher content of
      palmitic acid esterified in beta-position is to be tested in a double-blinded randomized
      controlled trial.

      The addition of prebiotics to an infant formula should favor growth of a beneficial
      bifidogenic intestinal flora and have positive effects on immunity, promote softer stool
      formation and short chain fatty acid content in the stools. Higher proportion of
      beta-palmitic acid esterified in 2nd position of the triglyceride should reduce formation of
      fatty acid-calcium soaps in the stools and promote calcium and fat absorption in the gut,
      therfor reduce symptoms of constipation and colics.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of gastrointestinal infections</measure>
    <time_frame>within first year of life</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of bifidobacteria on total stool bacteria</measure>
    <time_frame>after 6 and 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of infectious episodes (gastrointestinal, respiratory, fever episodes)</measure>
    <time_frame>within first year of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anthropometric parameters (gain in weight, length, head circumference)</measure>
    <time_frame>after 6 weeks, after 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptoms of food intolerance, constipation, colics</measure>
    <time_frame>after 6 weeks, 12 weeks intervention</time_frame>
    <description>number of episodes with colics, vomiting, abdominal bloating, intestinal gas; stool frequency, stool consistency, constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool biochemistry (calcium-fatty acid soaps, short chain fatty acids content in the stools)</measure>
    <time_frame>after 6 weeks, 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atopic manifestation</measure>
    <time_frame>within 1st year of life</time_frame>
    <description>incidence atopic dermatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>erythrocytesÂ´ fatty acid profile</measure>
    <time_frame>after 6 weeks intervention</time_frame>
    <description>palmitic acid, linolic acid, alpha-linoleic acid, AA, DHA, EPA etc content (erythrocytes membrane)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>calcium absorption</measure>
    <time_frame>after 6 weeks, 12 weeks intervention</time_frame>
    <description>urinary calcium-creatinin ratio, serum alkaline phosphatase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Infections</condition>
  <condition>Stool Flora</condition>
  <condition>Stool Biochemistry</condition>
  <condition>Constipation</condition>
  <condition>Food Intolerance</condition>
  <arm_group>
    <arm_group_label>Standard Formula</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard formula with no supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infant formula with higher beta-palmitate and supplemented GOS</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>new infant formula with prebiotics and beta-palmitate</intervention_name>
    <description>experimental infant formula as sole source of nutrition over first 12 weeks of life</description>
    <arm_group_label>experimental formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy term neonates

          -  gestational age 37 to 42 weeks

          -  birth weight 10th to 90th percentile (Voigt reference)

          -  infants being exclusively formula-fed at enrollment

        Exclusion Criteria:

          -  infants with high risk of atopic disease due to family history

          -  congenital disorder or syndrome with need for special diet / impairment of growth

          -  antibiotic medication prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Jochum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Waldkrankenhaus Protestant Hospital, Spandau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evangelisches Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2012</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Waldkrankenhaus Protestant Hospital, Spandau</investigator_affiliation>
    <investigator_full_name>Dr. Antonia Nomayo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>infant formula</keyword>
  <keyword>prebiotics</keyword>
  <keyword>beta-palmitate</keyword>
  <keyword>stool flora</keyword>
  <keyword>bifidogenic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

